Breaking News Instant updates and real-time market news.

ALDR

Alder Biopharmaceuticals

$11.40

-0.33 (-2.81%)

08:30
07/08/19
07/08
08:30
07/08/19
08:30

Alder Biopharmaceuticals to present new data on eptinezumab at AHS meeting

Alder BioPharmaceuticals announced that it will present new analyses of efficacy and quality of life data from its clinical trials for eptinezumab at the American Headache Society's 61st Annual Scientific Meeting in Philadelphia, PA being held on July 11-14, 2019. Eptinezumab is an investigational monoclonal antibody delivered by IV administration. It was designed for 100% bioavailability with high specificity and strong binding for rapid, robust and sustained suppression of calcitonin gene-related peptide. At the meeting, more than a dozen presentations related to eptinezumab's safety and efficacy of response in migraine prevention will be shared, including an analysis of 100% response rates for patients with episodic or chronic migraine who were treated with eptinezumab in the Phase 3 PROMISE-1 and PROMISE-2 clinical trials. Another key presentation will focus on the impact of eptinezumab on migraine severity and quality of life. Additional eptinezumab presentations at the meeting will feature a visual representation of the molecule's binding properties and further analyses related to safety and quality of life data. The U.S. Food and Drug Administration accepted the Biologics License Application (BLA) filing for eptinezumab in April 2019, and set a Prescription Drug User Fee Act target action date of February 21, 2020. If approved, eptinezumab will be the first-to-market IV therapy for migraine prevention.

  • 08

    Jul

  • 09

    Jul

  • 09

    Sep

  • 21

    Feb

ALDR Alder Biopharmaceuticals
$11.40

-0.33 (-2.81%)

02/25/19
PIPR
02/25/19
NO CHANGE
Target $28
PIPR
Overweight
Piper Jaffray maintains positive view of Alder Biopharmaceuticals' eptinezumab
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $28 price target on Alder Biopharmaceuticals after its Q4 results and update on eptinezumab this evening. The analyst maintains a positive view on the program and contends that "eptinezumab is the best suited agent for the most debilitated migraine patients", adding that the company could generate peak revenues of over $1B if it were to capture just the severe subset of patients.
04/04/19
PIPR
04/04/19
NO CHANGE
PIPR
Overweight
Piper Jaffray stays Overweight on Alder Biopharma, Amgen after Novartis filing
Piper Jaffray analyst Christopher Raymond maintains his Overweight rating on Alder Biopharma (ALDR) and Amgen (AMGN) after the filing by Novartis (NVS) alleging legal dispute with the latter about their migraine collaboration. The analyst says that Novartis tried to beat Amgen to the punch after entering agreement with Alder to manufacture eptinezumab, which prompted Amgen to terminate their commercialization agreement. Raymond adds that a resolution of this dispute could take a year or more but believes that investors may conclude that the spat reflects the value of anti-CGRP assets.
04/18/19
PIPR
04/18/19
NO CHANGE
PIPR
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
Following of survey of 99 neurologists done by his firm's partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly's (LLY) Emgality is lagging and that Teva's Ajovy appears to be gaining ground on Amgen's Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the" lack of clarity regarding when/where EBITDA will hit a trough." On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals' (ALDR) eptinezumab "appears to be particularly top-of-mind among migraine specialists."
05/28/19
LEER
05/28/19
INITIATION
Target $21
LEER
Outperform
Alder Biopharmaceuticals initiated with an Outperform at SVB Leerink
SVB Leerink analyst Marc Goodman initiated Alder Biopharmaceuticals with an Outperform and $21 price target.

TODAY'S FREE FLY STORIES

PEIX

Pacific Ethanol

$0.66

-0.0008 (-0.12%)

14:14
07/18/19
07/18
14:14
07/18/19
14:14
Hot Stocks
Hightower Advisors reports 8.17% passive stake in Pacific Ethanol »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$204.77

1.45 (0.71%)

, SWKS

Skyworks

$81.00

0.85 (1.06%)

14:12
07/18/19
07/18
14:12
07/18/19
14:12
On The Fly
Street Fight: Apple upgraded on 5G iPhone hopes as analysts diverge on Skyworks »

Citing greater confidence…

AAPL

Apple

$204.77

1.45 (0.71%)

SWKS

Skyworks

$81.00

0.85 (1.06%)

QCOM

Qualcomm

$74.67

-1.08 (-1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 31

    Jul

  • 07

    Aug

QCOM

Qualcomm

$74.67

-1.08 (-1.43%)

14:09
07/18/19
07/18
14:09
07/18/19
14:09
Initiation
Qualcomm initiated  »

Qualcomm initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

MSFT

Microsoft

$135.02

-1.21 (-0.89%)

, AMZN

Amazon.com

$1,958.83

-33.58 (-1.69%)

14:05
07/18/19
07/18
14:05
07/18/19
14:05
Periodicals
Trump says he's considering looking into Pentagon's JEDI contract, CNBC says »

U.S. President Donald…

MSFT

Microsoft

$135.02

-1.21 (-0.89%)

AMZN

Amazon.com

$1,958.83

-33.58 (-1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 25

    Jul

  • 06

    Aug

  • 08

    Aug

EGBN

Eagle Bancorp

$44.62

-8.81 (-16.49%)

14:02
07/18/19
07/18
14:02
07/18/19
14:02
Downgrade
Eagle Bancorp rating change  »

Eagle Bancorp downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 15

    Aug

  • 11

    Sep

  • 23

    Sep

14:00
07/18/19
07/18
14:00
07/18/19
14:00
General news
Breaking General news story  »

New York Federal Reserve…

13:55
07/18/19
07/18
13:55
07/18/19
13:55
Conference/Events
Federal Reserve Bank of New York president delivers keynote address »

New York Federal Reserve…

CAMP

CalAmp

$10.59

-0.23 (-2.13%)

13:55
07/18/19
07/18
13:55
07/18/19
13:55
Conference/Events
CalAmp participates in a conference call with Northland »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 24

    Jul

  • 06

    Aug

ADMP

Adamis Pharmaceuticals

$1.22

-0.03 (-2.41%)

13:54
07/18/19
07/18
13:54
07/18/19
13:54
Hot Stocks
Adamis Pharmaceuticals, kaleo Inc agree to settle all litigation »

Adamis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

PPG

PPG

$116.58

-0.025 (-0.02%)

13:54
07/18/19
07/18
13:54
07/18/19
13:54
Earnings
PPG sees unfavorable currency translation impact on Q3 sales of $30M-$50M »

"Looking ahead,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 05

    Aug

PPG

PPG

$116.49

-0.115 (-0.10%)

13:49
07/18/19
07/18
13:49
07/18/19
13:49
Hot Stocks
PPG says Q2 EPS impacted by lower global industrial production »

According to prepared…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 05

    Aug

ZBRA

Zebra Technologies

$180.92

-16.74 (-8.47%)

13:40
07/18/19
07/18
13:40
07/18/19
13:40
Options
Notable vol spike in Zebra Technologies as shares sell off »

Notable vol spike in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

TELL

Tellurian

$6.98

0.31 (4.65%)

13:40
07/18/19
07/18
13:40
07/18/19
13:40
Recommendations
Tellurian analyst commentary at Stifel »

Tellurian higher after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JLL

Jones Lang LaSalle

$140.05

0.585 (0.42%)

13:32
07/18/19
07/18
13:32
07/18/19
13:32
Conference/Events
Jones Lang LaSalle management to meet with Mizuho »

Meeting with EVP Monahan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 06

    Aug

  • 06

    Aug

GOSS

Gossamer Bio

$19.60

-0.48 (-2.39%)

13:30
07/18/19
07/18
13:30
07/18/19
13:30
Options
Gossamer Bio call volume spikes on November purchase wit shares at 52wk lows »

Gossamer Bio call volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
07/18/19
07/18
13:25
07/18/19
13:25
Conference/Events
Cowen healthcare/biotech analysts to hold an analyst/industry conference call »

Healthcare Technology…

PEP

PepsiCo

$132.17

-0.6 (-0.45%)

13:24
07/18/19
07/18
13:24
07/18/19
13:24
Periodicals
Breaking Periodicals news story on PepsiCo »

PepsiCo in talks to buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:20
07/18/19
07/18
13:20
07/18/19
13:20
General news
Treasury's $14 B 10-year TIPS sale was on the soft side »

Treasury's $14 B…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
07/18/19
07/18
13:17
07/18/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
07/18/19
07/18
13:16
07/18/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNIT

Uniti Group

$8.55

-0.03 (-0.35%)

13:15
07/18/19
07/18
13:15
07/18/19
13:15
Options
Uniti Group put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

13:09
07/18/19
07/18
13:09
07/18/19
13:09
General news
10-Yr TIPS Auction Coupon Rate data reported »

10-Yr TIPS Auction Coupon…

13:09
07/18/19
07/18
13:09
07/18/19
13:09
General news
10-Yr TIPS Auction Total Amount data reported »

10-Yr TIPS Auction Total…

TELL

Tellurian

$6.99

0.32 (4.80%)

13:05
07/18/19
07/18
13:05
07/18/19
13:05
Options
Tellurian call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:57
07/18/19
07/18
12:57
07/18/19
12:57
Conference/Events
Stephens architecture analysts to hold analyst/industry conference call nosymbol »

Analysts hold an…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.